drugset / Trial / NCT01942733

Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder

NCT01942733

Phase 3 Completed 44 enrolled H. Lundbeck A/S
NaSingle-groupOpen-labelTreatment

Summary

To assess effects of brexpiprazole on sleep patterns of depressed patients with sleep disturbances.

Timeline

Start
2013-09
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 2 mg Oral
Subject Brexpiprazole Small molecule 3 mg Oral

Indications